pharma · Multiple Myeloma · Ovarian Cancer
pharma&
pharmaand GmbH
pharmaand is a pharma organization headquartered in Wien, AT. Primary therapeutic focus areas include Multiple Myeloma, Ovarian Cancer. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s
Company details
- Status
- Public
- HQ
- Vienna, AT
- Founded
- 2017
- Employees
- 210
- Programs
- 3
- Drugs
- 16
- Patents
- 0
CO-338-087
Phase 3 · small molecule · Ovarian epithelial cancer, Malignant peritoneal neoplasm, advanced (FIGO stage III-IV), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer (who responded to front-line platinum-based chemotherapy), Fallopian tube cancer
CO-338-087 for Ovarian epithelial cancer, Malignant peritoneal neoplasm, advanced (FIGO stage III-IV), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer (who responded to front-line platinum-based chemotherapy), Fallopian tube cancer is a Phase 3 program (small_molecule) at pharmaand GmbH with 1 ClinicalTrials.gov record(s).
Internal code CO-338-087
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- pharmaand GmbH
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Ovarian epithelial cancer, Malignant peritoneal neoplasm, advanced (FIGO stage III-IV), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer (who responded to front-line platinum-based chemotherapy), Fallopian tube cancer
- Status
- active
- Trials
- 1